Phase 4 N=40 Inpatient Penicillin Allergy Delabeling Study
Penicillin Allergy · Penicillin Sensitivity · Penicillin Reaction
Primary: Number of Participants With Confirmed Allergy Status — 28; 6; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=103 Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
COVID-19 · Corona Virus Infection
Primary: Participants Who Had a Reaction to an Initial or Additional Dose of the Pfizer-BioNTech or Moderna COVID-19 mRNA Vaccine, or Who Had Long COVID — 71; 2; 1; 1 Participants
Phase 2 N=16 The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
Systemic Allergic Reaction
Primary: Proportion of Participants Who Had Recurrent Systemic Allergic Reaction to Vaccine — 0.125 Proportion of participants
Phase 3 N=32 Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Dermatitis, Phototoxic
Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site
Phase 2 N=176 Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
Staphylococcus Aureus
Primary: Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports — 37; 40; 28; 36 events
Phase 2 N=66 Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Phase 2 N=16 Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass
Congenital Heart Disease
Primary: Serum Inflammatory Mediators Post CPB — 3.8; 3.4; 90.9; 78.3 ng/mL — p=>0.05
Phase 2 N=24 Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.
Prostate Cancer
Primary: Adverse Event — 22; 2; 4; 0 Adverse Events — p=0.001
Phase 2 N=61 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Hematologic Malignancies · Graft vs Host Disease
Primary: 100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) — 22 percentage of participants
N/A N=61 From Short-term Surgical Missions Towards Sustainable Partnerships
Global Surgery · Medical Missions
Primary: Q7: Country Where the Last Mission Took Place — 2; 2; 1; 1 Participants
N/A N=10 Magnet for Corneal Foreign Bodies
Corneal Foreign Body
Primary: Success Rate — 1 Participants
N/A N=10 Salsalate for Insulin Resistance in Schizophrenia
Schizophrenia · Insulin Resistance
Primary: Side Effects of Salsalate — 3 participants
Phase 3 N=137 Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants
Dermatitis, Photoallergic
Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site
N/A N=20 Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study
Emergence Reaction · Procedural Sedation
Primary: Emergence Reaction
Phase 2 N=40 Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions
Infusion Reaction · Monoclonal Antibody
Primary: Number of Participants With Standard Infusion Reactions (SIR) at Cycle 1 and During Subsequent Cycles of Monoclonal Antibody Infusion — 14; 26; 4; 35 Participants